Data Dictionary for SWOG S1400I Clinical Dataset (NCT02785952-D1-Dataset.csv)

Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for deidentification purposes or have undergone further data cleaning).

Blanks indicate missing value

Variable Name	Variable description	Type	Code	Code definition
ALTPATID	Pseudo patient ID	Char		
DERIVED_RACE	Race	Char	В	Black
			М	Multi-Racial
			N	Native American
			Р	Pacific Islander
			S	Asian
			U	Unknown
			W	White
SEX	Sex	Char	F	Female
SEX	Sex	Char	М	Male
			N	No
HISPANIC	Hispanic Ethnicity	Char	U	Unknown
			Υ	Yes
AU 18 48-T	Number of prior			
NUMPT	therapies for stage IV or recurrent disease (0 or more)	Num		
Number of pr	Number of prior		One	
	therapies (stratification factor)	Char	Two or more	
CIGHIST1	Smoking status	Char	CURRENT	Current smoker
			FORMER	Former smoker
			NEVER	Never smoked
			<5	<5% of body weight
P6WTLOSS			<10	5% to <10% of body
	Weight loss in past 6	Char		weight
	months		<20	10% to <20% of body
				weight
			>=20	≥20% of body weight

1		1	T
ECOG performance status	Num	0	Fully active, able to carryout on all predisease performance withoutrestriction.
		1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g.light housework, office work.
Brain Metastases at	Char	N	No Yes
	Char	· -	
	Cnar		No Yes
			No
	Char		Yes
·		-	No
	Char		Yes
Overall survival	Num		
Indicator of death (1) or	Num	0	Censored for death
		1	Death
Progression free survival (calculated), months	Num		
Indicator of progression (1) or censored for progression (0)	Num	0	Censored for progression
		1	Progression
Best objective response		CR	Complete response
	Char	PR	Partial response
		UPR	Unconfirmed complete response
		STA	Stable disease
		INC	Increasing disease
		SYMP	Symptomatic deterioration
		NASS	Inadequate assessment
Date of substudy registration to first documentation of response, among responders, months	Num		
	Brain Metastases at baseline Liver metastases at baseline Prior radiation therapy (localized) Prior radiation therapy (with curative intent) Overall survival (calculated), months Indicator of death (1) or censored for death (0) Investigator- Assessed Progression free survival (calculated), months Indicator of progression (1) or censored for progression (0) Best objective response	Brain Metastases at baseline Liver metastases at baseline Prior radiation therapy (localized) Prior radiation therapy (with curative intent) Overall survival (calculated), months Indicator of death (1) or censored for death (0) Investigator- Assessed Progression free survival (calculated), months Indicator of progression (1) or censored for progression (1) or censored for progression (0) Best objective response Char Char Char	ECOG performance status Brain Metastases at baseline Liver metastases at baseline Prior radiation therapy (localized) Prior radiation therapy (with curative intent) Overall survival (calculated), months Indicator of death (1) or censored for death (0) Investigator- Assessed Progression (1) or censored for progression (0) Best objective response Date of substudy registration to first documentation of response, among Num 1 Num Char N N N N N O 1 0 1 CR PR UPR Char STA INC SYMP NASS

tte_resprv2	Duration of response [among responders]	Num		
	(calculated), months			
			Nivolumab	
ARMNAME	Treatment Arm (Nivolumab/Ipilimumab or nivolumab)	Char	Nivolumab + Ipilimumab	
	,			
timetooff	Duration of protocol treatment from registration to off treatment date, months	Num		
OFFTX	Indicator of off-	Num	0	No
OTTIX	treatment status		1	Yes
			DEAD	Death
			ОТН	Other – not protocol specified
	Reason off treatment	Char	PROG	Progression/relapse
OFFREASON			REF	Refusal unrelated to adverse event
			TSC	Adverse events or side effects
			<i>u u</i>	Missing value
age_cat	Age at randomization, years	Char		
CLINTOX	Evaluable for toxicities	Char	N	No
			Υ	Yes
tmb_num	Tumor Mutational Burden (mt/Mb)	Num		
PDL1_num	Programmed Death- Ligand 1 expression (%)	Num		
num_cycles	Number of treatment cycles	Num		
			0	None
			1	Rarely
nro diarrhoa may	DPO diarrhoa froguesa	Num	2	Occasionally
pro_diarrhea_max	PRO diarrhea frequency	Num	3	Frequently
			4	Almost constantly

			0	None
pro_diarrhea_max_adjust	PRO diarrhea frequency, baseline adjustment	Num	1	Rarely
			2	Occasionally
			3	Frequently
			4	Almost constantly
			0	None
	PRO fatigue severity	Num	1	Mild
			2	Moderate
pro_fatigueS_max			3	Severe
			4	Very severe
			0	None
pro_fatigueS_max_adjust	PRO fatigue severity, baseline adjustment	Num	1	Mild
			2	Moderate
			3	Severe
			4	Very severe
			0	Not at all
pro_fatiguel_max	PRO fatigue interference	Num	1	A little bit
			2	Somewhat
			3	Quite a bit
			4	Very much

			0	Not at all
pro_fatiguel_max_adjust	PRO fatigue interference, baseline adjustment	Num	1	A little bit
			2	Somewhat
			3	Quite a bit
			4	Very much
			0	None
			1	Mild
		Num	2	Moderate
pro_itch_max	PRO itching severity		3	Severe
			4	Very severe
		Num	0	None
			1	Mild
	PRO itching severity,		2	Moderate
pro_itch_max_adjust	baseline adjustment		3	Severe
			4	Very severe